TD Asset Management’s LENZ Therapeutics LENZ Stock Holding History

TD Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Sell	24,610 -2,368	-9%	-$33.3K	﹤0.01%	1219
2025 Q4	$432K	Sell	26,978 -4,422	-14%	-$129K	﹤0.01%	1183
2025 Q3	$1.46M	Buy	+31,400	New	+$1.15M	﹤0.01%	1026
2025 Q2	–	Sell	-34,828	Closed	-$895K	–	1265
2025 Q1	$895K	Sell	34,828 -68,172	-66%	-$1.68M	﹤0.01%	1081
2024 Q4	$2.97M	Buy	103,000 +74,690	+264%	+$2.28M	﹤0.01%	899
2024 Q3	$681K	Buy	+28,310	New	+$628K	﹤0.01%	1255

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

TD Asset Management's LENZ Position: Q1 2026 in Review

TD Asset Management reduced its LENZ Therapeutics (LENZ) stake by 8.8% in Q1 2026, selling an estimated $33.3K and leaving 24,610 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

TD Asset Management first reported a position in LENZ in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.97M in Q4 2024. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

TD Asset Management held 24,610 shares of LENZ Therapeutics worth $225K as of Q1 2026.
TD Asset Management sold 2,368 LENZ Therapeutics shares in Q1 2026, an estimated $33.3K.
LENZ Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1219 holding.
TD Asset Management first reported a position in LENZ Therapeutics in Q3 2024 and has held it in 6 quarters since.
TD Asset Management's LENZ Therapeutics position peaked at $2.97M in Q4 2024.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.